Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06448039 · ClinicalTrials.gov registry record · Phase 1

In-office Repair of Chronic Tympanic Membrane Perforations

A Phase 1 study, sponsored by D. Bradley Welling, MD, PhD.

Active
Registry status
Phase 1
Development phase
20
Enrollment target

NCT06448039 is a Phase 1 study that is active but no longer recruiting, run by D. Bradley Welling, MD, PhD. The registered enrollment target is 20 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06448039, a Phase 1 study, is active but no longer recruiting, sponsored by D. Bradley Welling, MD, PhD.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
20 participants
Enrollment target

Study Summary

The goal of this clinical trial is to compare the application of fibroblast growth factor 2 (FGF2) with normal saline for the healing of chronic tympanic membrane (TM) perforations. This is an extension of a prior study. The main question it aims to answer is: Will modifications to our prior surgical trial provide higher success rates in obtaining complete closure of chronic tympanic membrane perforations? Twenty participants will be randomized in a controlled study to FGF2 or saline in a 3:1 ratio and the total tympanic membrane closure compared.

Interventions

  • DRUG Fibroblast Growth Factor 2
  • DRUG Saline control

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2024-06-15
Est. Completion 2026-12-30
Phase Phase 1

Sponsor

D. Bradley Welling, MD, PhD

3 total trials

What the Registry Record Tells You About NCT06448039

The ClinicalTrials.gov registry entry for NCT06448039 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is D. Bradley Welling, MD, PhD, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Fibroblast Growth Factor 2 is the first listed.

NCT06448039 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT06448039 about?

NCT06448039 is a clinical study titled "In-office Repair of Chronic Tympanic Membrane Perforations". The goal of this clinical trial is to compare the application of fibroblast growth factor 2 (FGF2) with normal saline for the healing of chronic tympanic membrane (TM) perforations. This is an extension of a prior study. The main question it aims to answer is: Will modifications to our prior surgic...

What is the current status of trial NCT06448039?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2024-06-15. Estimated completion is 2026-12-30.

What interventions are being tested in trial NCT06448039?

The interventions under investigation include: Fibroblast Growth Factor 2 (DRUG), Saline control (DRUG).

Who is sponsoring clinical trial NCT06448039?

This trial is sponsored by D. Bradley Welling, MD, PhD, which has 3 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.